Cargando…

Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program

OBJECTIVE: To reduce the number of unnecessary biopsies in patients with benign prostatic disease, however, without missing significant PCa the present study re-evaluates the age-dependent PSA cut-offs in the Tyrol Prostate Cancer (PCa) early detection program. PATIENTS AND METHODS: The study popula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heidegger, Isabel, Fritz, Josef, Klocker, Helmut, Pichler, Renate, Bektic, Jasmin, Horninger, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517762/ https://www.ncbi.nlm.nih.gov/pubmed/26218594 http://dx.doi.org/10.1371/journal.pone.0134134

Ejemplares similares

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008
por: Oberaigner, Willi, et al.
Publicado: (2011)

High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance
por: Heidegger, Isabel, et al.
Publicado: (2015)

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer()
por: Heidegger, Isabel, et al.
Publicado: (2013)

Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response
por: Kafka, Mona, et al.
Publicado: (2022)

Antidiabetic drugs influence molecular mechanisms in prostate cancer
por: Pircher, Andreas, et al.
Publicado: (2018)

ASCO 2018: highlights of urothelial cancer and prostate cancer
por: Pichler, Renate, et al.
Publicado: (2018)

Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer
por: Schaefer, G, et al.
Publicado: (2013)

Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature
por: Pircher, Andreas, et al.
Publicado: (2019)

Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer
por: Ladurner, Michael, et al.
Publicado: (2021)

Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
por: Heidegger, Isabel, et al.
Publicado: (2018)

Gender-related Outcome in Bladder Cancer Patients undergoing Radical Cystectomy
por: Pichler, Renate, et al.
Publicado: (2017)

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008
por: Schröder, Fritz H., et al.
Publicado: (2011)

Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study
por: Pichler, Renate, et al.
Publicado: (2017)

Acceptance of female urologists among patients with suspected prostate disease
por: Steinkohl, Fabian, et al.
Publicado: (2021)

Genetically adjusted PSA levels for prostate cancer screening
por: Kachuri, Linda, et al.
Publicado: (2023)

Evaluation of the PI-RADS Scoring System for Classifying mpMRI Findings in Men with Suspicion of Prostate Cancer
por: Junker, Daniel, et al.
Publicado: (2013)

Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model
por: Mühlberger, Nikolai, et al.
Publicado: (2017)

Cholesterol pathway the Achilles heel in prostate cancer metastasis
por: Heidegger, Isabel, et al.
Publicado: (2018)

Long term disease free survival with multimodal therapy in small cell bladder cancer
por: Heidegger, Isabel, et al.
Publicado: (2016)

Potentials and Limitations of Real-Time Elastography for Prostate Cancer Detection: A Whole-Mount Step Section Analysis
por: Junker, Daniel, et al.
Publicado: (2012)

Mitochondrial Haplogroups and Control Region Polymorphisms Are Not Associated with Prostate Cancer in Middle European Caucasians
por: Mueller, Edith E., et al.
Publicado: (2009)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies
por: Bertok, Tomas, et al.
Publicado: (2020)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
por: Kafka, Mona, et al.
Publicado: (2020)

KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
por: Schäfer, Georg, et al.
Publicado: (2021)

The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis
por: Heidegger, Isabel, et al.
Publicado: (2014)

Adenomatoid tumor of the testis mimicking malignant testicular cancer on multiparametric ultrasound
por: Pichler, Renate, et al.
Publicado: (2018)

Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer
por: Klocker, Helmut, et al.
Publicado: (2020)

The Impact of Cand1 in Prostate Cancer
por: Eigentler, Andrea, et al.
Publicado: (2020)

The (68)Ga/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
por: Maffey-Steffan, Johanna, et al.
Publicado: (2019)

The Use of Dietary Supplements to Alleviate Androgen Deprivation Therapy Side Effects during Prostate Cancer Treatment
por: Dueregger, Andrea, et al.
Publicado: (2014)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Metastatic prostate cancer in the modern era of PSA screening
por: Fontenot, Philip A., et al.
Publicado: (2017)

Characterisation of the main PSA glycoforms in aggressive prostate cancer
por: Gratacós-Mulleras, Anna, et al.
Publicado: (2020)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo
por: Ofer, Philipp, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u3jksaneodk4tmr1clm6q63256